Journal of Clinical Oncology 1992: Vol 10 Index

47 Pages·1992·10.4 MB·English

AUTHOR INDEX
Abeloff M, see Allred DC — see Rubin EH
Abeloff MD, see Clark GM — see Weisdorf DJ
— see Tormey DC Anderson KC, see Soiffer RJ
Acaba L, see Gulati S Anderson L, see Hancock BW
Achterrath W, see Gatzemeier U Anderson P, see Alberts DS
Ackery D, see Lashford LS Andrien F, see Bosly A
Acord P, see MacKenzie MR Andrieu J-M, see Tourani J-M
Ad Hoc Committee on Cancer Pain of the American Society Andriole GL. Serum prostate-specific antigen: The most
of Clinical Oncology. Cancer pain assessment and useful tumor marker (editorial), 1205
treatment curriculum guidelines, 1976 Andrulis I, see Levine MN
Adamo DO, see Sarosy G Anselmo AP, see Biti GP
Adamson PC, Balis FM, McCully CL, Godwin KS, Poplack Antman K, Ayash L, Elias A, Wheeler C, Hunt M, Eder JP,
DG. Methotrexate pharmacokinetics following ad- Teicher BA, Critchlow J, Bibbo J, Schnipper LE, Frei
ministration of recombinant carboxypeptidase-G, in E Ill. A phase II study of high-dose cyclophospha-
rhesus monkeys, 1359 mide, thiotepa, and carboplatin with autologous
— see Smith MA marrow support in women with measurable ad-
Adler KM, see Lum BL vanced breast cancer responding to standard-dose
— see Yahanda AM therapy, 102
Adrover E, see Martin M — see Ayash LJ
Advanced colorectal cancer meta-analysis project. Modula- Appelbaum F, see Chopra R
tion of fluorouracil by leucovorin in patients with ad- Appelbaum FR, see Bensinger WI
vanced colorectal cancer: Evidence in terms of re- — see Clift RA
sponse rate, 896 Applewhite A, see Meyers PA
Agerlin N, see Bach F Ariyoshi Y, see Fukuoka M
Ahn C, see Margolin KA Armand JP, see Robert J
Aronson FR, see Weiss GR
Aisner J, Goutsou M, Maurer LH, Cooper R, Chahinian P,
Aronson L, see Smith MA
Carey R, Skarin A, Slawson R, Perry MC, Green
Arriagada R, Kramar A, Le Chevalier T, De Cremoux H.
MR. Intensive combination chemotherapy, concur-
Competing events determining relapse-free survival
rent chest irradiation, and warfarin for the treatment
in limited small-cell lung carcinoma, 447
of limited-disease small-cell lung cancer: A Cancer
Artim R, see MacKenzie MR
and Leukemia Group B pilot study, 1230
Assendelft A, see Niiranen A
Akman SA, see Margolin KA
Atiq OT, see Kelsen D
Albertioni F, see Liliemark J
Atkins MB, Vachino G, Tilg HJ, Karp DD, Robert NJ,
Alberts DS, Green S, Hannigan EV, O’Toole R, Stock-No-
Kappler K, Mier JW. Phase I evaluation of thrice-
vack D, Anderson P, Surwit EA, Malvlya VK, Nah-
daily intravenous bolus interleukin-4 in patients with
has WA, Jolles CJ. Improved therapeutic index of
refractory malignancy, 1802
carboplatin plus cyclophosphamide versus cisplatin
— see Weiss GR
plus cyclophosphamide: Final report by the South-
Atkinson CH, see Ellis PA
west Oncology Group of a phase III randomized trial
Atkinson K, see Copelan EA
in stages III] and IV ovarian cancer, 706
Attisano C, see Foa R
Alexander E Ill, see Loeffler JS
Attubato M, see Speyer JL
Alexanian R, see Dimopoulos MA
Audy J-CR, see Rougier P
Alison RE, see Sturgeon JFG
Auzanneau G, see Bosly A
Allred DC, Clark GM, Tandon AK, Molina R, Tormey DC,
Avalos BR, see Copelan EA
Osborne CK, Gilchrist KW, Mansour EG, Abeloff
Ayash L, see Antman K
M, Eudey L, McGuire WL. HER-2/neu in node-nega-
Ayash LJ, Wright JE, Tretyakov O, Gonin R, Elias A,
tive breast cancer: Prognostic significance of overex-
Wheeler C, Eder JP, Rosowsky A, Antman K, Frei E
pression influenced by the presence of in situ carci-
III. Cyclophosphamide pharmacokinetics: Correla-
noma, 599
tion with cardiac toxicity and tumor response, 995
Almadrones L, see Markman M
Altschuler G, see Castleberry RP
Alvord WG, see Smith JW Il Bacchi M, see Cocconi G
Ambinder R, see Wagner JE Bach F, Agerlin N, Sorensen JB, Rasmussen TB, Domber-
Ames FC, see Buzdar AU nowsky P, Sorensen PS, Hansen HH. Metastatic spi-
Anastasopoulos E, see Kosmidis PA nal cord compression secondary to lung cancer, 1781
Anbazhagan R, see Gusterson BA Bachaud JM, see de Forni M
Andersen J, see Nichols CR Bacoyiannis C, see Kosmidis PA
Andersen JW, Harrington D. Meta-analyses need new pub- Bader JL, see Lichter AS
lication standards (editorial), 878 Bafaloukos D, see Kosmidis PA
Journal of Clinical Oncology, Vol 10, No 12 (December), 1992 : pp 1989-2013
1990 AUTHOR INDEX
Bagnulo S, see De Bernardi B K, Poplack DG. Phase I/II trial and pharmacokinet-
Baiocchi G, see Scambia G ics of intrathecal diaziquone in refractory meningeal
Bajorin DF, see Ilson DH malignancies, 143
Baker DK, Relling MV, Pui C-H, Christensen ML, Evans Berger R, see Detourmignies L
WE, Rodman JH. Increased teniposide clearance Bergeron C, see Michel G
with concomitant anticonvulsant therapy, 311 Bergsagel DE, Myeloma, melphalan, and meta-analysis (edi-
Balis FM, see Adamson PC torial), 178
— see Berg SL Bernadet P, see de Forni M
— see Smith MA Bernasconi C, see Vitolo U
Banks PLC, see Vogler WR Bernaudin F, see Michel G
Bar MH, see Weiss GR Bernstein ML, Leclerc JM, Bunin G, Brisson L, Robison L,
Barakat R, see Markman M Shuster J, Byrne T, Gregory D, Hill G, Dougherty G,
Barbui T, see Vitolo U Scriver C, Lemieux B, Tuchman M, Woods WG. A
Barna B, see Budd GT population-based study of neuroblastoma incidence,
Barr RD, see Feeny D survival, and mortality in North America, 323
Bartolucci AA, see Vogler WR Bertini M, see Vitolo U
Barylak EJ, see Tormey DC Bertrand Y, see Oberlin O
Bast RC Jr, see Daly L Bettelheim R, see Gusterson BA
Bastert G, see Diel IJ — see Neville AM
Bastian A, see Foss FM Beutler E, see Kay AC
Battaglia F, see Scambia G Bevilacqua P, see Gasparini G
Bauters F, see Detourmignies L Bey P, see Oberlin O
— see Morel P Biagini C, see Biti GP
Baxevanis CN, see Kosmidis PA Bianco JA, see Bensinger WI
Beatty P, see Bensinger WI Bibbo J, see Antman K
Beck TM, Hesketh PJ, Madajewicz S, Navari RM, Pender- Biddinger PW, see Yahalom J
grass K, Lester EP, Kish JA, Murphy WK, Hains- Biesma B, see Postmus PE
worth JD, Gandara DR, Bricker LJ, Keller AM, Mor- Biggs JC, see Copelan EA
timer J, Galvin DV, House KW, Bryson JC. Strati- Biondi A, see Rovelli A
fied, randomized, double-blind comparison of Bisagni G, see Cocconi G
intravenous ondansetron administered as a multiple- Biti GP, Cimino G, Cartoni C, Magrini SM, Anselmo AP,
dose regimen versus two single-dose regimens in the Maurizi Enrici RM, Bellesi GP, Bosi A, Papa G,
prevention of cisplatin-induced nausea and vomit- Giannarelli D, Ponticelli P, Papi MG, Rossi Ferrini
ing, 1969 PL, Biagini C, Mandelli F. Extended-field radiother-
Behar C, see Oberlin O apy is superior to MOPP chemotherapy for the treat-
Belanger C, see Michel G ment of pathologic stage I-I[A Hodgkin’s disease:
Belfort R Jr, see Sanda MG Eight-year update of an Italian prospective random-
Belhani M, see Tourani J-M ized study, 378
Bell S, see Dropcho EJ Bitran JD, see Williams SF
Belldegrun A, see Figlin RA Black PMcL, see Loeffler JS
Bellesi GP, see Biti GP Blackstein ME, see Burkes RL
Bellone G, see Foa R Blaise D, see Michel G
Belt RJ, see Ravdin PM Blake K, see Soiffer RJ
Benedet JL, see Hoskins PJ Blakley RL, see Santana VM
Benjamin RS, see Kleinerman ES Blanchette VS, see Coppes MJ
— see Vadhan-Raj S Blend MJ, Ronan SG, Salk DJ, Das Gupta TK. Role of
Bennett MH, see Hancock BW technetium 99m-labeled monoclonal antibody in the
Bensinger WI, Buckner CD, Clift RA, Petersen FB, Bianco management of melanoma patients, 1330
JA, Singer JW, Appelbaum FR, Dalton W, Beatty P, Blend R, see Sturgeon JFG
Fefer A, Storb R, Thomas ED, Hansen JA. Phase I Blevins C, see Margolin KA
study of busulfan and cyclophosphamide in prepara- Blum RH, see Speyer JL
tion for allogeneic marrow transplant for patients Blumenstein B, see Loehrer PJ Sr
with multiple myeloma, 1492 Bobo H, see Goffman TE
— see Clift RA Boldt DH, see Weiss GR
Benyunes MC, see Thompson JA Bolufer P, Ricart E, Lluch A, Vazquez C, Rodriguez A, Ruiz
Benz LA, see Thompson JA A, Llopis F, Garcia~-Conde J, Romero R. Aromatase
Beran M, see Kantarjian HM activity and estradiol in human breast cancer: Its re-
Berchuck A, see Rodriguez GC lationship to estradiol and epidermal growth factor
Berg DT, see Rubin EH receptors and to tumor-node-metastasis staging, 438
Berg SL, Balis FM, Zimm S, Murphy RF, Holcenberg J, Bonadonna G, see Gianni AM
Sato J, Reaman G, Steinherz P, Gillespie A, Doherty Boni C, see Cocconi G
AUTHOR INDEX
Boni L, see De Bernardi B Brusamolino E, see Vitolo U
Boracchi P, see Gasparini G Bruzzi P, see De Bernardi B
Borden EC, see Greiner JW Bryant G, see Wilson WH
Bordigoni P, see Michel G Bryson JC, see Beck TM
Borowitz M, see Trueworthy R Buchanan GR, see Wofford MM
Borst JR, see Ravdin PM Buckley M, see Kelsen D
Bosi A, see Biti GP Buckner CD, see Bensinger WI
Bosl GJ, The late effects of germ cell tumor chemotherapy: — see Clift RA
More data are needed (editorial), 1375 Budd GT, Murthy S, Finke J, Sergi J, Gibson V, Medendorp
— see Ilson DH S, Barna B, Boyett J, Bukowski RM. Phase I trial of
Bosly A, Coiffier B, Gisselbrecht C, Tilly H, Auzanneau G, high-dose bolus interleukin-2 and interferon alfa-2a
Andrien F, Herbrecht R, Legros M, Devaux Y, Jau- in patients with metastatic malignancy, 804
bert J, Pignon B, Michaux J-L, Humblet Y, Dupriez Buescher ES, see Vadhan-Raj S
B, Thyss A, Lederlin P for the Group d’Etudes des Bugat R, see de Forni M
Lymphomes de I’Adulte. Bone marrow transplanta- Bukman A, see Osanto S
tion prolongs survival after relapse in aggressive-lym- Bukowski RM, Tangen C, Lee R, Macdonald JS, Einstein
phoma patients treated with the LNH-84 regimen, AB Jr, Peterson R, Fleming TR. Phase II trial of
1615 chlorozotocin and fluorouracil in islet cell carci-
Botet J, see Kemeny N noma: A Southwest Oncology Group study, 1914
Boudjema B, see de Forni M — see Budd GT
Bouffet E, see Frappaz D Bulova SI, see Lazarus HM
Bova FJ, see Ellis ER Bundow D, see Krown SE
Boyett J, see Budd GT Bunin G, see Bernstein ML
Brahimi S, see Tourani J-M Burger P, see Friedman HS
Braine HG, see Graham ML Burgers M, see Bramwell VHC
Bramwell VHC, Burgers M, Sneath R, Souhami R, van Oos- Burkes RL, Ginsberg RJ, Shepherd FA, Blackstein ME,
terom AT, Voute PA, Rouesse J, Spooner D, Craft Goldberg ME, Waters PF, Patterson GA, Todd T,
AW, Somers R, Pringle J, Malcolm AJ, van der Eij- Pearson FG, Cooper JD, Jones D, Lockwood G. In-
ken J, Thomas D, Uscinska B, Machin D, van Glab- duction chemotherapy with mitomycin, vindesine,
beke M. A comparison of two short intensive adju- and cisplatin for stage III unresectable non-small-cell
vant chemotherapy regimens in operable osteosar- lung cancer: Results of the Toronto phase II trial, 580
coma of limbs in children and young adults: The first Biirki K, see Gusterson BA
study of the European Osteosarcoma Intergroup, Burns W, see Wagner JE
1579 Burroughs J, see Jacobs C
Bregni M, see Gianni AM Burroughs JN, see Jodrell DI
Breneman DL, see Foss FM Burrows W, see Speyer JL
Breneman JC, see Foss FM Bush WH Jr, see Thompson JA
Brennan M, see Kelsen D Buter J, see Sleijfer DTh
Brennan MF, see Gaynor JJ Buzdar AU, Hortobagyi GN, Kau S-WC, Smith TL, Fras-
Brescia FJ, Portenoy RK, Ryan M, Krasnoff L, Gray G. chini G, Holmes FA, Gutterman JU, Hug VM, Sin-
Pain, opioid use, and survival in hospitalized patients gletary SE, Ames FC, McNeese MD. Adjuvant ther-
with advanced cancer, 149 apy with escalating doses of doxorubicin and
Breslin M, see Shea TC cyclophosphamide with or without leukocyte a-in-
Brice P, see Morel P terferon for stage II or III breast cancer, 1540
Bricker LJ, see Beck TM — see Jaiyesimi IA
Brisigotti M, see De Bernardi B Byrne M, see Coates A
Brisson L, see Bernstein ML Byrne T. see Bernstein ML
Brodsky I, see Lazarus HM
Brophy NA, see Lum BL Cabanillas F, see Redman JR
— see Yahanda AM Caillot D, see Solary E
Brothers M, see Dropcho EJ Callender DPE, see Mueller BU
Broun GO, see Roth BJ Canal P, see de Forni M
Broxmeyer HE, see Vadhan-Raj S Canellos GP, The second chance for advanced Hodgkin’s
Brugger W, Frisch J, Schulz G, Pressler K, Mertelsmann R, disease (editorial), 175
Kanz L. Sequential administration of interleukin-3 Canetta R, see Swenerton K
and granulocyte-macrophage colony-stimulating fac- Canetta RM, see Jodrell DI
tor following standard-dose combination chemother- Caputo C, see Lerman C
apy with etoposide, ifosfamide, and cisplatin, 1452 Carbone A, see Foa R
Brugia M, see Cocconi G — see Tirelli U
Brugiere L, see Frappaz D Carey R, see Aisner J
Brunat-Mentigny M, see Oberlin O Carey RW, see Strauss GM
1992 AUTHOR INDEX
Carli M, see De Bernardi B the European Bone Marrow Transplant Group reg-
Carmichael J, see Swenerton K istry data, 1690
Carpi A, see Cocconi G Choyke P, see Myers C
Carrera CJ, see Kay AC Christensen ML, see Baker DK
Carrié C, see Oberlin O Christian M, see Shea TC
Carrié D, see de Forni M Cicale MJ, see Ellis ER
Carroll A, see Trueworthy R Cimino G, see Biti GP
Carson DA, see Kay AC Ciobanu N, see Lazarus HM
Carter C, see Wilson WH Ciocca DR, see Osborne CK
Carter D, see Haffty BG Civin CI, see Graham ML
Carter M, see Mulhern RK — see Kuerbitz SJ
— see Schell MJ Claessens RAMJ, see Oyen WJG
Carter RD, see Ravdin PM Clark GM, Mathieu M-C, Owens MA, Dressler LG, Eudey
Cartoni C, see Biti GP L, Tormey DC, Osborne CK, Gilchrist KW, Man-
Carver CS, see Pozo C sour EG, Abeloff MD, McGuire WL. Prognostic sig-
Casado A, see Martin M nificance of S-phase fraction in good-risk, node-nega-
Casale F, see De Bernardi B tive breast cancer patients, 428
Casasnovas R-O, see Solary E — see Allred DC
Casper ES, see Gaynor JJ Clark KC, see Pozo C
Cassidy J, see Myers C Clark PI, see Girling DJ
Cassileth PA, see Hochster HS Clarke DH, Martinez AA. Identification of patients who are
Cassuto-Viguier E, see Milano G at high risk for locoregional breast cancer recurrence
Castaigne S, see Detourmignies L after conservative surgery and radiotherapy: A review
Castiglione M, see Gusterson BA article for surgeons, pathologists, and radiation and
— see Neville AM medical oncologists, 474
Castleberry RP, Shuster JJ, Altschuler G, Smith IE, Clarke-Pearson DL, see Rodriguez GC
Nitschke R, Winick N, McWilliams N, Joshi V, Clift RA, Buckner CD, Appelbaum FR, Schoch G, Petersen
Hayes FA. Infants with neuroblastoma and regional FB, Bensinger WI, Sanders J, Sullivan KM, Storb R,
lymph node metastases have a favorable outlook Singer J, Hansen JA, Thomas ED. Allogeneic
after limited postoperative chemotherapy: A Pediat- marrow transplantation during untreated first relapse
ric Oncology Group study, 1299 of acute myeloid leukemia, 1723
Cavallero GB, see Vitolo U — see Bensinger WI
Ceci G, see Cocconi G Coates A, Gebski V, Signorini D, Murray P, McNeil D,
Chabner BA, Camptothecins (editorial), 3 Byrne M, Forbes JF for the Australian New Zealand
Chahinian P, see Aisner J Breast Cancer Trials Group. Prognostic value of qual-
Champlin RE, see Schiller GJ ity-of-life scores during chemotherapy for advanced
Chapman D, see Kelsen D breast cancer, 1833
Chappell RJ, see Ritter MA Cocconi G, Bisagni G, Ceci G, Bacchi M, Boni C, Brugia M,
Chastagner P, see Frappaz D Carpi A, Di Costanzo F, Franciosi V, Gori S, Indelli
Chauffert B, see Solary E M, Passalacqua R. Low-dose aminoglutethimide
Chawla SP, see Vadhan-Raj S with and without hydrocortisone replacement as a
Cherng N, see Jacobs C first-line endocrine treatment in advanced breast
Cherng NC, see Roth BJ cancer: A prospective randomized trial of the Italian
Cheson BD, The purine analogs—A therapeutic beauty con- Oncology Group for Clinical Research, 984
test (editorial), 352, 868 Cohen AM, see Minsky BD
— see Smith MA Cohen HJ, see Roth BJ
Chevreau C, see de Forni M Coiffier B, see Bosly A
Childs A, see Raghavan D Collin CF, see Gaynor JJ
— see Sanda MG Collins C, see Thompson JA
Chisesi T, see Foa R Collins J, see Gusterson BA
Chlebowski RT, Sayre J, Frank-Stromborg M, Lillington — see Neville AM
LB. Current attitudes and practice of American Soci- Colls BM, see Ellis PA
ety of Clinical Oncology-member clinical oncologists Colombani PM, see Graham ML
regarding cancer prevention and control, 164 Colonna P, see Tourani J-M
Choi NC, see Strauss GM Comis R, see Hudes GR
Chomienne C, see Detourmignies L Comotti B, see Vitolo U
Chompret A, see Oberlin O Conlon KC, see Smith JW II
Chopra R, Goldstone AH, Pearce R, Philip T, Petersen F, Connaghan GD, see Smith MA
Appelbaum F, De Vol E, Ernst P. Autologous versus Conter V, see Rovelli A
allogeneic bone marrow transplantation for non- Conti F, see Francini G
Hodgkin’s lymphoma: A case-controlled analysis of Conti JA, see Kemeny N
AUTHOR INDEX
Cook J, see Goffman TE Danforth DN Jr, see Lichter AS
Cook PA, see Mead GM d’Angelo T, see Lichter AS
— see Read G D’Angio GJ, see Corn BW
Coombes RC, see Jones AL — see Maity A
Cooper BW, see Lazarus HM Das Gupta TK, see Blend MJ
Cooper JD, see Burkes RL Davidson H, see MacKenzie MR
Cooper M, see Myers C Davidson NE. Out of the courtroom and into the clinic (edi-
Cooper R, see Aisner J torial), 517
Cooper S, see Vadhan-Raj S Davis BW, see Neville AM
Copelan EA, Biggs JC, Avalos BR, Szer J, Cunningham I, Dawson N, see Myers C
Klein JP, Atkinson K, Kapoor N, Klein JL, Downs De Bernardi B, Carli M, Casale F, Corciulo P, di Monteze-
K, Tutschka PJ. Radiation-free preparation for alloge- molo LC, De Laurentis C, Bagnulo S, Brisigotti M,
neic bone marrow transplantation in adults with Marchese N, Garaventa A, Felici L, Lo Curto M, Vis-
acute lymphoblastic leukemia, 237 coli C, Tamaro P, Rogers D, Boni L, Dini G, Bruzzi
Coppes MJ, Zandvoort SWH, Sparling CR, Poon AO, P. Standard-dose and high-dose peptichemio and cis-
Weitzman S, Blanchette VS. Acquired von Wille- platin in children with disseminated poor-risk neuro-
brand disease in Wilms’ tumor patients, 422 blastoma: Two studies by the Italian Cooperative
Coral F, see Soiffer RJ Group for Neuroblastoma, 1870
Corciulo P, see De Bernardi B De Cicco M, see Tirelli U
Corn BW, Goldwein JW, Evans I, D’Angio GJ. Outcomes in De Cremoux H, see Arriagada R
low-risk babies treated with half-dose chemotherapy de Forni M, Malet-Marino MC, Jaillais P, Shubinski RE,
according to the Third National Wilms’ Tumor Bachaud JM, Lemaire L, Canal P, Chevreau C,
Study, 1305 Carrié D, Soulié P, Roché H, Boudjema B, Mihura J,
Corstens FHM, see Oyen WJG Martino R, Bernadet P, Bugat R. Cardiotoxicity of
Costa P, see Kemeny N high-dose continuous infusion fluorouracil: A pro-
Costa SD, see Diel IJ spective clinical study, 1795
Cotelingam JD, see Foss FM de Gast GC, see Verdonck LF
Cottler-Fox M, see Wilson WH de Jong J, Geijssen GJ, Munniksma CN, Vermorken JB,
Cowan K, see Lichter AS van der Vijgh JF. Plasma pharmacokinetics and phar-
Cowan KH, see Wilson WH macodynamics of a new prodrug N-/-leucyldoxorubi-
Cox K, see Raghavan D cin and its metabolites in a phase I clinical trial, 1897
Craft AW, see Bramwell VHC De Laat JAPM, see Osanto S
Cram GP Jr, see Daly L De Laurentis C, see De Bernardi B
Crawford ED, see Loehrer PJ Sr de Pauw BE, see Oyen WJG
Crawford J, see Roth BJ de Smet MD, see Sanda MG
Creekmore SP, see Smith JW II De Vincenzo R, see Scambia G
Creger RJ, see Lazarus HM De Vol E, see Chopra R
Crilley P, see Lazarus HM de Vries EGE, see Postmus PE
Crist W, see Trueworthy R — see Sleijfer DTh
Crist WM, see Kuerbitz SJ DeAngelis LM, Yahalom J, Thaler HT, Kher U. Combined
Critchlow J, see Antman K modality therapy for primary CNS lymphoma, 635
Crom W, see Santana VM DeBoer G, see Sagman U
Crown J, see Gulati $ DeGregorio MW, see Osborne CK
Cullen MH, see Read G — see Wiebe VJ
Cunningham D, see Mansi J Deisseroth A, see Kantarjian HM
Cunningham I, see Copelan EA deKernion J, see Figlin RA
Cunningham J, see Ziegler LD Dekker AW, see Lokhorst HM
Cunnion RE, see Sarosy G — see Verdonck LF
Curti BD, see Smith JW II Delasalle K, see Dimopoulos MA
Curtin J, see Markman M Delmoor E, see Lerman C
Delmotte J-J, see Lienard D
da Costa F, see Mansi J DelRosario RB, see Kaminski MS
Dachowski LJ, see Goffman TE Demard F, see Milano G
D’Agay M-F, see Morel P Demchak PA, see Weiss GR
Dalton T, see Jacobs C Demers L, see Leitzel K
Dalton W, see Bensinger WI Demory JL, see Detourmignies L
Daly L, Ferguson J, Cram GP Jr, Hars V, George SL, deMoss E, see Lichter AS
McCarty KS Jr, Bast RC Jr. Comparison of a novel Denham JW, see Gill PG
assay for breast cancer mucin to CA15-3 and carcino- Dennin R, see Ziegler LD
embryonic antigen, 1057 Dershaw DD, see Yahalom J
Damsma O, see Postmus PE Desablens B, see Touran! J-M
1994 AUTHOR INDEX
Desch CE, Lasala MR, Smith TJ, Hillner BE. The optimal Eder JP, see Antman K
timing of autologous bone marrow transplantation in — see Ayash LJ
Hodgkin’s disease patients after a chemotherapy re- Egorin MJ, see Jodrell DI
lapse, 200 Ehsan MN, see Lum BL
Deshmukh AA, see Lee CR Einhorn LH, see Jacobs C
Detourmignies L, Castaigne S, Stoppa AM, Harousseau JL, — see Loehrer PJ Sr
Sadoun A, Janvier M, Demory JL, Sanz M, Berger R, — see Nichols CR
Bauters F, Chomienne C, Fenaux P. Therapy-related — see Roth BJ
acute promyelocytic leukemia: A report on 16 cases, Einstein AB Jr, see Bukowski RM
1430 Einzig AI, Wiernik PH, Sasloff J, Runowicz CD, Goldberg
Devaux Y, see Bosly A GL. Phase II study and long-term follow-up of pa-
DeVita VT Jr, see Longo DL tients treated with taxol for advanced ovarian adeno-
Devitt PG, see Gill PG carcinoma, 1748
di Celle PF, see Foa R Eisenberg PD, see LeVeque FG
Di Costanzo F, see Cocconi G Elias A, see Antman K
di Montezemolo LC, see De Bernardi B — see Ayash LJ
Di Nicola M, see Gianni AM Elias AD, see Strauss GM
Diaz-Rubio E, see Martin M Elias D, see Rougier P
Diel IJ, Kaufmann M, Goerner R, Costa SD, Kaul S, Bastert Ellis ER, Marcus RB Jr, Cicale MJ, Springfield DS, Bova FJ,
G. Detection of tumor cells in bone marrow of pa- Graham-Pole J, Enneking WF, Spanier SS, Million
tients with primary breast cancer: A prognostic factor RR. Pulmonary function tests after whole-lung irra-
for distant metastasis, 1534 diation and doxorubicin in patients with osteogenic
Dimopoulos MA, Goldstein J, Fuller L, Delasalle K, Alex- sarcoma, 459
anian R. Curability of solitary bone plasmacytoma, Ellis PA, Fitzharris BM, George PM, Robinson BA, Atkin-
587 son CH, Colls BM. Fasting plasma lipid measure-
Dini G, see De Bernardi B ments following cisplatin chemotherapy in patients
DiPetrillo T, see Wazer DE with germ cell tumors, 1609
Djuric L, see Jeremic B Elson PJ, see Loehrer PJ Sr
Dnistrian A, see Rusch VW Elwood LJ, see Smith JW II
Dodge R, see Rodriguez GC Engstrom P, see Lerman C
Doherty K, see Berg SL Enker WE, see Minsky BD
Doherty M, see Gulati S Enneking WF, see Ellis ER
Dombernowsky P, see Bach F Ensley JF, see Forastiere AA
— see Pedersen-Bjergaard J Ernst P, see Chopra R
Donehower RC, see Rowinsky EK Errante D, see Tirelli U
Donovan A, see Leichman L Escat J, see Rougier P
Doroshow JH, see Margolin KA Esperou-Bourdeau H, see Michel G
— see Weiss GR Estey EH, see Kantarjian HM
Dorr TM, see Ravdin PM Etienne MC, Milano G, Frenay M, Renee N, Francois E,
Dougherty G, see Bernstein ML Thyss A, Schneider M, Namer M. Pharmacokinetics
Downs K, see Copelan EA and pharmacodynamics of medroxyprogesterone
Dressler LG, see Clark GM acetate in advanced breast cancer patients, 1176
Dropcho EJ, Rosenfeld SS, Morawetz RB, Vitek J, Brothers — see Milano G
M, Gorum T, Bell S, Gillespie GY, Glantz M, Maha- Ettinger DS, see Rowinsky EK
ley MS Jr, Schold SC Jr for the CNS Cancer Consor- Eudey L, see Allred DC
tium. Preradiation intracarotid cisplatin treatment of — see Clark GM
newly diagnosed anaplastic gliomas, 452 Evans I, see Corn BW
Drouin P, see Swenerton K Evans WE, see Baker DK
Du M, see Grunewald R Evans WK, see Feld R
Dubousset J, see Oberlin O — see Sagman U
Dubowy RL, see Graham ML — see Shepherd FA
Duffey PL, see Longo DL Evrard D, see Mattson K
Dumas M, see Solary E Ewalenko P, see Lienard D
Duncan W, see Sturgeon JFG
Dupriez B, see Bosly A Fabian C, see Ravdin PM
— see Morel P Fairclough D, see Mulhern RK
Dutcher JP, see Weiss GR Fairey RN, see Hoskins PJ
Falkson G, see Raats JI
Easton D, see Jones AL — see Sesterhenn IA
Eddy DM. High-dose chemotherapy with autologous bone — see Tormey DC
marrow transplantation for the treatment of meta- Falkson HC, see Raats JI
static breast cancer, 657 Falletta JM, see Friedman HS
AUTHOR INDEX 1995
Farinacci GC, see LeVeque FG mous-cell carcinoma of the head and neck: A South-
Faucher K, see Grunewald R west Oncology Group study, 1245
Feeny D, Furlong W, Barr RD, Torrance GW, Rosenbaum — see Rowinsky EK
P, Weitzman S. A comprehensive multiattribute sys- Forbes JF, see Coates A
tem for classifying the health status of survivors of Ford HT, see Jones AL
childhood cancer, 923 Foss FM, Ihde DC, Breneman DL, Phelps RM, Fischmann
Fefer A, see Bensinger WI AB, Schechter GP, Linnoila I, Breneman JC, Cote-
— see Thompson JA lingam JD, Ghosh BC, Steinberg SM, Lynch JW,
Feit F, see Speyer JL Phares JC, Stocker JL, Bastian A, Sausville EA. Phase
Feld R, Wierzbicki R, Walde PLD, Shepherd FA, Evans II study of pentostatin and intermittent high-dose re-
WK, Gupta S, Shannon P, Lassus M. Phase I-II study combinant interferon alfa-2a in advanced mycosis
of high-dose epirubicin in advanced non-small-cell fungoides/Sézary syndrome, 1907
lung cancer, 297 Fossa SD, Qvist H, Stenwig AE, Lien HH, Ous S, Giercksky
— see Sagman U KE. Is postchemotherapy retroperitoneal surg-
Feldman E, see Kantarjian HM ery necessary in patients with nonseminomatous
Felici L, see De Bernardi B testicular cancer and minimal residual tumor
Fenaux P, see Detourmignies L masses? 569
Fossa SD, see Mead GM
— see Morel P
Fox RM, see Lazarus HM
Fenoglio C, see Vadhan-Raj S
Fox S, see Hudes GR
Fenton RG, see Smith JW II
Francini G, Gonnelli S, Petrioli R, Conti F, Paffetti P, Gen-
Fenton RM, see Smith MA
nari C. Treatment of bone metastases with dichlo-
Ferguson J, see Daly L
romethylene bisphosphonate, 591
Ferrandina G, see Scambia G
Franciosi V, see Cocconi G
Ferrans V, see Speyer JL
Francis IR, see Kaminski MS
Ferretti GA, see LeVeque FG
Francois E, see Etienne MC
Feusner J, see Smith MA
Fielding SL, see Lashford LS Frankel J, see Minsky BD
Frankel L, see Trueworthy R
Fig LM, see Kaminski MS
Frank-Stromborg M, see Chlebowski RT
Figlin RA, Belldegrun A, Moldawer N, Zeffren J, deKernion
Franzén L, see Henriksson R
J. Concomitant Administration of recombinant hu-
Frappaz D, Michon J, Hartmann O, Bouffet E, Lejars O,
man interleukin-2 and recombinant interferon alfa-
Rubie H, Gentet JC, Chastagner P, Sariban E, Bru-
2A: An active outpatient regimen in metastatic renal
giere L, Zucker JM, Lemerle J, Philip T. Etoposide
cell carcinoma, 414
and carboplatin in neuroblastoma: A French Society
Finberg R, see Talcott JA
of Pediatric Oncology phase II study, 1592
Findlay PA, see Lichter AS
— see Michel G
Fine HA, see Loeffler JS
Fraschini G, see Buzdar AU
Finke J, see Budd GT Fraumeni JF Jr, see Li FP
Fischer D, see Haffty BG Freedman AS, see Soiffer RJ
Fischmann AB, see Foss FM Freeman A, see Soiffer RJ
Fisher GA, see Yahanda AM Frei E Ill, see Antman K
Fisher H, see Nichols CR — see Ayash LJ
Fisher RI, see Weiss GR Frenay M, see Etienne MC
Fitzharris BM, see Ellis PA — see Milano G
Flaum MA, see Vogler WR Frenck RW Jr, see Vadhan-Raj S
Fleming TR, see Bukowski RM Fridman M, see Silber JH
Fletcher B, see Meyer WH Friedman HS, Krischer JP, Burger P, Oakes WJ, Hocken-
Flomenberg N, see Krown SE berger B, Weiner MD, Falletta JM, Norris D, Ragab
Flower MA, see Lashiord LS AH, Mahoney DH Jr, Whitehead MV, Kun LE.
Flynn S, see Haffty BG Treatment of children with progressive or recurrent
Foa R, Guarini A, di Celle PF, Trentin L, Gillio Tos A, brain tumors with carboplatin or iproplatin: A Pediat-
Bellone G, Carbone A, Attisano C, Massaia M, Raspa- ric Oncology Group randomized phase II study, 249
dori D, Pizzolo G, Chisesi T, Lauria F, Semenzato G. Friedman MA, see Smith MA
Constitutive production of tumor necrosis factor-al- Friedrich C, see Gaynor JJ
pha in hairy cell leukemia: Possible role in the patho- Frisch J, see Brugger W
genesis of the cytopenia(s) and effect of treatment Fuerst M, see Leichman L
with interferon-alpha, 954 Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa
Forastiere AA, Metch B, Schuller DE, Ensley JF, Hutchins K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S,
LF, Triozzi P, Kish JA, McClure S, VonFeldt E, Wil- Masuda N, Nakajima S, Taguchi T for the CPT-11
liamson SK, Von Hoff DD. Randomized compari- Lung Cancer Study Group. A phase II study of CPT-
son of cisplatin plus fluorouracil and carboplatin plus 11, a new derivative of camptothecin, for previously
fluorouracil versus methotrexate in advanced squa- untreated non-small-cell lung cancer, 16
1996 AUTHOR INDEX
— see Masuda N or granulocyte colony-stimulating factor infusion
Fuller L, see Dimopoulos MA makes high-dose etoposide a safe outpatient regimen
Furlong W, see Feeny D that is effective in lymphoma and myeloma patients,
1955
Gadia M, see Gregg RW Gibson V, see Budd GT
Gajewski JL, see Schiller GJ Giercksky KE, see Fossa SD
Galili N, see Wasserman R Gietema JA, see Postmus PE
Gallo E, see Vitolo U Gilchrist KW, see Allred DC
Gallot D, see Rougier P — see Clark GM
Galvin DV, see Beck TM — see Tormey DC
Gandara D, see MacKenzie MR Gilewski T, see Williams SF
Gandara DR, see Beck TM Gill I, see Nichols CR
Garaventa A, see De Bernardi B Gill PG, Denham JW, Jamieson GG, Devitt PG, Yeoh E,
Garcia-Conde J, see Bolufer P Olweny C. Patterns of treatment failure and prognos-
Gardembas-Pain M, see Michel G tic factors associated with the treatment of esopha-
Gasparini G, Gullick WJ, Bevilacqua P, Sainsbury JRC, geal carcinoma with chemotherapy and radiotherapy
Meli S, Boracchi P, Testolin A, La Malfa G, Pozza F. either as sole treatment or followed by surgery, 1037
Human breast cancer: Prognostic significance of the Gillespie A, see Berg SL
expression of the c-erb-B-2 oncoprotein compared Gillespie GY, see Dropcho EJ
with epidermal growth factor receptor, DNA ploidy, Gillio Tos A, see Foa R
and conventional pathologic features, 686 Ginn D, see Kelsen D
Gastrointestinal Tumor Study Group. Radiation therapy Ginsberg R, see Sagman U
and fluorouracil with or without semustine for the Ginsberg RJ, see Burkes RL
treatment of patients with surgical adjuvant adenocar- Girling DJ, Clark PI. Randomized trials in the treatment of
cinoma of the rectum, 549 cancer of the esophagus (editorial), 1031
Gatzemeier U, Hossfeld DK, Neuhauss R, Reck M, Ach- Gisselbrecht C, see Bosly A
terrath W, Lenaz L. Combination chemotherapy — see Morel P
with carboplatin, etoposide, and vincristine as first- Giudici G, see Rovelli A
line treatment in small-cell lung cancer, 818 Gjedde SB, see Pedersen-Bjergaard J
Gaynor ER, see Weiss GR Glantz M, see Dropcho EJ
Gaynor JJ, Tan CC, Casper ES, Collin CF, Friedrich C, Shiu Glatstein E, see Goffman TE
M, Hajdu SI, Brennan MF. Refinement of clinico- — see Lichter AS
pathologic staging for localized soft tissue sarcoma of — see Longo DL
the extremity: A study of 423 adults, 1317 — see Rothenberg ML
Gazet JC, see Jones AL Glick JH, see Weisdorf DJ
Gebski V, see Coates A Gluckman E, see Michel G
Geertsen PF, Hermann GG, von der Maase H, Steven K. Godwin KS, see Adamson PC
Treatment of metastatic renal cell carcinoma by con- Goerner R, see Diel IJ
tinuous intravenous infusion of recombinant inter- Goffman TE, Dachowski LJ, Bobo H, Oldfield EH, Stein-
leukin-2: A single-center phase II study, 753 berg SM, Cook J, Mitchell JB, Katz D, Smith R, Glat-
Gehan E, see Heyn R stein E. Long-term follow-up on National Cancer In-
Geijssen GJ, see de Jong J stitute phase I/II study of glioblastoma multiforme
Gelber RD, see Gusterson BA treated with iododeoxyuridine and hyperfractionated
— see Neville AM irradiation, 264
— see Waber DP Gold JWM, see Krown SE
Geller RB, see Wagner JE Goldberg GL, see Einzig AI
Gennari C, see Francini G Goldberg ME, see Burkes RL
Gentet JC, see Frappaz D Goldbloom EP, see Jodrell DI
Gentet J-C, see Oberlin O Goldhirsch A, see Gusterson BA
George C, see MacKenzie MR — see Neville AM
George PM, see Ellis PA Goldman L, see Talcott JA
George SL, see Daly L Goldspiel B, see Wilson WH
Gerber LH, see Lichter AS Goldstein D, see Greiner JW
Gerber MC, see Vogler WR Goldstein J, see Dimopoulos MA
Ghio R, see Vitolo U Goldstone AH, see Chopra R
Ghosh BC, see Foss FM Goldwein JW, see Corn BW
Giaccone G, see Mattson K — see Maity A
Giannarelli D, see Biti GP — see Silber JH
Gianni AM, Bregni M, Siena S, Magni M, Di Nicola M, Golembe BL, see Wofford MM
Lombardi F, Tarella C, Pileri A, Bonadonna G. Golouh R, see Gusterson BA
Granulocyte-macrophage colony-stimulating factor — see Neville AM
AUTHOR INDEX 1997
Gonin R, see Ayash LJ noma patients enhances expression of tumor-asso-
— see Lerner A ciated glycoprotein-72 and carcinoembryonic anti-
— see Soiffer RJ gen on malignant ascites cells, 735
Gonnelli S, see Francini G Gresik MV, see Kuerbitz SJ
Gonzales G, see Leith CP Gress J, see Mueller BU
Goodlow JL, see Jodrell DI Gribble M, see MacKenzie MR
— see Roth BJ Griffin C, see Wagner JE
Goodnough LT, see Jacobs C Griffin J, see Kleinerman ES
Gore M, see Mansi J Gnigolato P, see Gusterson BA
Gori S, see Cocconi G Grochow LB, see Rowinsky EK
Gorrell CR, see Lichter AS Grogan TM, see Leith CP
Gorum T, see Dropcho EJ Groshen S, see Leichman L
Gosland MP, see Lum BL — see Mitchell MS
— see Yahanda AM Groves ES, see Sanda MG
Gospodarowicz MK, see Sturgeon JFG Grujicic D, see Jeremic B
Goss PE, see Shepherd FA Grunewald R, Kantarjian H, Du M, Faucher K, Tarassoff P,
Gosselin B, see Morel P Plunkett W. Gemcitabine in leukemia: A phase I
Goutsou M, see Aisner J clinical, plasma, and cellular pharmacology study,
Gouvernet J, see Michel G 406
Gouzi JL, see Rougier P Grygiel J, see Raghavan D
Graham ML, Yeager AM, Leventhal BG, Wiley JM, Civin Guadagni F, see Greiner JW
Cl, Strauss LC, Hurwitz CA, Dubowy RL, Wharam Guarini A, see Foa R
MD Jr, Colombani PM, Rowley SD, Braine HG, Gucalp R, Ritch P, Wiernik PH, Sarma PR, Keller A, Rich-
Santos GW. Treatment of recurrent and refractory man SP, Tauer K, Neidhart J, Mallette LE, Siegel R,
pediatric solid tumors with high-dose busulfan and VandePol CJ. Comparative study of pamidronate
cyclophosphamide followed by autologous bone disodium and etidronate disodium in the treatment
marrow rescue, 1857 of cancer-related hypercalcemia, 134
Graham-Pole J, see Ellis ER — see Lazarus HM
Gralla RJ, see Grant SC — see Weiss GR
Grant SC, Gralla RJ, Kris MG, Orazem J, Kitsis EA. Single- Guilhot F, see Tourani J-M
agent chemotherapy trials in small-cell lung cancer, Gulati S, Yahalom J, Acaba L, Reich L, Motzer R, Crown J,
1970 to 1990: The case for studies in previously Toia M, Igarashi T, Lemoli R, Hanninen E, Doherty
treated patients, 484 M. Treatment of patients with relapsed and resistant
Gratecos N, see Michel G non-Hodgkin’s lymphoma using total body irradia-
Gray G, see Brescia FJ tion, etoposide, and cyclophosphamide and autolo-
Gray R, see Tormey DC gous bone marrow transplantation, 936
Greco FA, see Hainsworth JD Gullick WJ, see Gasparini G
— see Roih BJ Gupta S, see Feld R
— see Waits TM Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Séve-
Green MD, see Hochster HS Séderbergh J, Anbazhagan R, Styles J, Rudenstam
— see Speyer JL C-M, Golouh R, Reed R, Martinez-Tello F, Tiltman
Green MR, see Aisner J A, Torhorst J, Grigolato P, Bettelheim R, Neville
— see Strauss GM AM, Biirki K, Castiglione M, Collins J, Lindtner J,
Green S, see Alberts DS Senn, H-J for the International (Ludwig) Breast
— see Ravdin PM Cancer Study Group. Prognostic importance of c-
Greenberg R, see Hudes GR erbB-2 expression in breast cancer, 1049
Greer J, see Nichols CR Gutin PH, see Wilson CB
Gregg RW, Molepo JM, Monpetit VJA, Mikael NZ, Red- Gutterman J, see Kantarjian HM
mond D, Gadia M, Stewart DJ. Cisplatin neurotoxic- Gutterman JU, see Buzdar AU
ity: The relationship between dosage, time, and plati- — see Vadhan-Raj S
num concentration in neurologic tissues, and mor- Guy H, see Solary E
phologic evidence of toxicity, 795
Greggi S, see Scambia G Habrand JL, see Oberlin O
Gregory D. see Bernstein ML Habrand J-L, see Oberlin O
Gregory WM, Richards MA, Malpas JS. Combination che- Haddad R, see Sagman U
motherapy versus melphalan and prednisolone in the Haffty BG, Toth M, Flynn S, Fischer D, Carter D. Prognos-
treatment of multiple myeloma: An overview of pub- tic value of DNA flow cytometry in the locally recur-
lished trials, 334 rent, conservatively treated breast cancer patient,
Greiner JW, Guadagni F, Goldstein D, Smalley RV, Borden 1839
EC, Simpson JF, Molinolo A, Schlom J. Intraperito- Hagemeister FB, see Redman JR
neal administration of interferon-gamma to carci- Haggard M, see Trueworthy R
1998 AUTHOR INDEX
Haggard ME, see Wofford MM Hendricks CB, see Rowinsky EK
Hahka-Kemppinen M, see Pyrhénen S Henriksson R, Franzén L, Littbrand B. Effects of sucralfate
Hainsworth JD, Johnson DH, Greco FA. Cisplatin-based on acute and late bowel discomfort following radio-
combination chemotherapy in the treatment of therapy of pelvic cancer, 969
poorly differentiated carcinoma and poorly differen- Herbrecht R, see Bosly A
tiated adenocarcinoma of unknown primary site: Re- Herman S, see Sturgeon JFG
sults of a 12-year experience, 912 Hermann GG, see Geertsen PF
— see Beck TM Hermans J, see Osanto S
— see Waits TM Herndier B, see Shiramizu B
Hajdu SI, see Gaynor JJ Herndon JE, see Strauss GM
Hakes T, see Markman M Herrmann F, Helfrich SG, Lindermann A, Schleiermacher
Halsey J, see Lum BL E, Huber Ch, Mertelsmann R. Elevated circulating
— see Yahanda AM levels of tumor necrosis factor predict unresponsive-
Hammond GD, see Smith MA ness to treatment with interferon alfa-2b in chronic
Hancock BW, Hudson GV, Hudson BV, Bennett MH, Mac- myelogenous leukemia, 631
Lennan KA, Haybittle JL, Anderson L, Linch DC. Herve P, see Michel G
LOPP alternating with EVAP is superior to LOPP Hesketh PJ, see Beck TM
alone in the initial treatment of advanced Hodgkin’s Hestdal K, see Smith JW II
disease: Results of a British National Lymphoma In- Hewett KD, see Hays DM
vestigation trial, 1252 Heyn R, Raney RB Jr, Hays DM, Tefft M, Gehan E, Web-
Hande KR, see Waits TM ber B, Mauer HM. Late effects of therapy in patients
Hanjani P, see Lerman C with paratesticular rhabdomyosarcoma, 614
Hannigan EV, see Alberts DS Heyne KH, Lippman SM, Lee JJ, Lee JS, Hong WK. The
Hannigan J, see MacKenzie MR incidence of second primary tumors in long-term
Hanninen E, see Gulati S survivors of small-cell lung cancer, 1519
Hansen HH, see Bach F Hill G, see Bernstein ML
— see Kristensen CA Hillner BE, see Desch CE
Hansen JA, see Bensinger WI Hittelman WN, see Smith MA
— see Clift RA — see Vadhan-Raj S
Hansen M, see Pedersen-Bjergaard J Ho WG, see Schilier GJ
Hanson CA, see Kaminski MS Hochster H, see Jacobs C
Hardy RI, see Yahanda AM — see Speyer JL
Harel W, see Mitchell MS Hochster HS, Kim K, Green MD, Mann RB, Neiman RS,
Harousseau JL, see Detourmignies L Oken MM, Cassileth PA, Stott P, Ritch P, O’Connell
Harrington D, see Andersen JW MJ. Activity of fludarabine in previously treated
Harris M, see Trueworthy R non-Hodgkin’s low-grade lymphoma: Results of an
Harris SD, see Pozo C Eastern Cooperative Oncology Group study, 28
Hars V, see Daly L Hockenberger B, see Friedman HS
Hartmann O, see Frappaz D Holcenberg J, see Berg SL
Harvey H, see Leitzel K Holian A, see Vadhan-Raj S
Hasegawa K, see Fukuoka M Holmes FA, see Buzdar AU
Hassan M, see Liliemark J Hong WK, see Heyne KH
Hawkins MJ, see Weiss GR Horowitz ME, see Smith MA
Hay JM, see Rougier P Hortobagyi G, see Jaiyesimi IA
Hayakawa K, see Ziegler LD Hortobagyi GN, see Buzdar AU
Haybittle JL, see Hancock BW Horwich A, see Mead GM
Hayes FA, see Castleberry RP — see Read G
Hays DM, Landsverk J, Sallan SE, Hewett KD, Patenaude Hoskins PJ, O’Reilly SE, Swenerton KD, Spinelli JJ, Fairey
AF, Schoonover D, Zilber SL, Ruccione K, Siegel SE. RN, Benedet JL. Ten-year outcome of patients with
Educational, occupational, and insurance status of advanced epithelial ovarian carcinoma treated with
childhood cancer survivors in their fourth and fifth cisplatin-based multimodality therapy, 1561
decades of life, 1397 Hoskins W, see Markman M
— see Heyn R Hossfeld DK, see Gatzemeier U
Healey J, see Meyers PA House KW, see Beck TM
Heelan R, see Kelsen D Hovgaard DJ, Nissen NI. Effect of recombinant human
Heimans JJ, see van Rijswijk REN granulocyte-macrophage colony-stimulating factor
Helfrich SG, see Herrmann F in patients with Hodgkin’s disease: A phase I/II
Helin H, see Toikkanen S study, 390
Heller G, see Meyers PA Hubbard SM, see Longo DL
Hellstrom I, see Ziegler LD Huber Ch, see Herrmann F
Hellstrom KE, see Ziegler LD Hudes GR, Greenberg R, Krigel RL, Fox S, Scher R, Litwin